Month: December 2013

Rockstar Consortium US LP et. al.v. Google Inc

Gopikrishnan M, an intern at Khurana and Khurana, Advocates and IP Attorneys, looks at Google Inc. been accused of infringing technology related to its searching technology itself. Yet another high-tech and high-profile patent war is on, this one involving a combined attack on the search giant’s core technology. Google is being sued for direct patent infringement … Continue reading Rockstar Consortium US LP et. al.v. Google Inc

Read more »

Copyrights Enjoyed By Musicians

Sanyukta Biswas, an intern at Khurana and Khurana, Advocates and IP Attorneys, looks at the rights of singer, lyricist and composer that have been incorporated by the 2012 amendment. Once upon a time in India even the most noted of film artists and musicians could not secure themselves financially despite their brilliance. In an infamous legal … Continue reading Copyrights Enjoyed By Musicians

Read more »

Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios

We are happy to inform you all that IIPRD and Khurana & Khurana, in association with Cantor Colburn (US) and Fukami Patent Office (Japan) are holding an International Patent Symposium covering all major and relevant Pharmaceutical/Biotechnology Related Patent issues in the month of February, 2014 in India. The Two-Days International Symposium would be covering Strategies for Managing … Continue reading Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios

Read more »

Sofosbuvir: The Next Pre-Grant Opposition Target by I-MAK

After anti–influenza drug Tamiflu (Oseltamivir Phosphate) and antiretroviral drug Viread, Gilead Sciences is again back in news, this time with its hepatitis C (HCV) drug Sofosbuvir. Like Tamiflu and Viread pre-grant opposition, Sofosbuvir patent application is also facing pre-grant opposition. Non-profit group I-MAK (Initiative for medicines access and knowledge) has filed a pre-grant opposition against … Continue reading Sofosbuvir: The Next Pre-Grant Opposition Target by I-MAK

Read more »